15th International Drug Resistance Workshop, 13-17 June 2006, Sitges, Spain
3 August 2006. Related: Conference reports, Resistance.
Intl Drug Resistance Workshop 15 Sitges 2006
Resistance implications of monotherapy with lopinavir/r (Kaletra)
3 August 2006. Related: Conference reports, Resistance.
Ritonavir reduces virological failure and resistance in treatment naive patients treated with atazanavir
3 August 2006. Related: Conference reports, Resistance.
Resistance to darunavir (TMC-114): predicting responses for treatment experienced patients
3 August 2006. Related: Conference reports, Resistance.
Epidemiological studies and transmission of resistance: evidence for optimism or issues with interpretation?
3 August 2006. Related: Conference reports, HIV prevention and transmission, Resistance.
K103N containing variants persist longer in women with subtype D and with higher viral loads
3 August 2006. Related: Conference reports, Resistance.
No subtype-based differences in baseline levels of K103N-containing variants in women receiving single dose nevirapine
3 August 2006. Related: Conference reports, Resistance.
Phenotypic NNRTI resistance and genetic diversity in antiretroviral naive women
3 August 2006. Related: Conference reports, Resistance.
High prevalence of the K65R mutation in Botswana patients treated with ddI/d4T-based regimens
3 August 2006. Related: Conference reports, Resistance.
Potential for easier selection of K65R mutation with tenofovir pressure in subtype C HIV-1 isolates
3 August 2006. Related: Conference reports, Resistance.
Categorisation of transmitted HIV drug resistance using the WHO/CDC HIV drug resistance threshold survey method may be useful in resource limited settings
3 August 2006. Related: Conference reports, Resistance.
Limitations in online tools to identify HIV-1 subtypes
3 August 2006. Related: Conference reports, Resistance.
Resistance implications from PrEP and microbicide studies in macaques
3 August 2006. Related: Conference reports, Resistance.
Low-level resistance linked to treatment failure: a role for more sensitive testing for naive patients
3 August 2006. Related: Conference reports, Resistance.
Testing for resistance after starting treatment
3 August 2006. Related: Conference reports, Resistance.
5th International Workshop on HIV Drug Resistance, 4-8 June 2001, Scottsdale, Arizona
30 July 2001. Related: Conference reports.
Anti-HIV immune responses and partial viral suppression
30 July 2001. Related: Conference reports, Resistance.
HIV resistance, phenotypic drug susceptibility and viral fitness
30 July 2001. Related: Conference reports, Resistance.
SWATCH – alternating antiretroviral regimens
30 July 2001. Related: Conference reports, Resistance.
Structured treatments interruptions
30 July 2001. Related: Conference reports, Resistance.
Importance of additional active drugs for NNRTI-naive patients using NNRTI-based salvage regimens
30 July 2001. Related: Conference reports, Resistance.
NNRTI and PI drug plasma levels are as critical as drug sensitivity in achieving treatment success in antiretroviral experienced patients
30 July 2001. Related: Conference reports, Resistance.
Increased prevalence of transmission of drug resistant HIV and reduced response in newly infected subjects in nine US cities
30 July 2001. Related: Conference reports, Resistance.
Role of codon-69 variants in reduced susceptibility to nucleoside analogues
30 July 2001. Related: Conference reports, Resistance.
Selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug naive people
30 July 2001. Related: Conference reports, Resistance.
Nucleoside resistance pathways may differ between HIV-1 and HIV-2
30 July 2001. Related: Conference reports, Resistance.
Role of Y318F mutation in NNRTI resistance
30 July 2001. Related: Conference reports, Resistance.